CN Patent

CN114469984A — 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物

Assigned to Alnylam Pharmaceuticals Inc · Expires 2022-05-13 · 4y expired

What this patent protects

本发明涉及抑制受试者中PCSK9基因表达的方法，以及使用靶向PCSK9基因的RNAi试剂例如双链RNAi试剂来治疗患有脂质障碍例如高脂血症的受试者的治疗性和预防性方法。

USPTO Abstract

本发明涉及抑制受试者中PCSK9基因表达的方法，以及使用靶向PCSK9基因的RNAi试剂例如双链RNAi试剂来治疗患有脂质障碍例如高脂血症的受试者的治疗性和预防性方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN114469984A
Jurisdiction
CN
Classification
—
Expires
2022-05-13
Drug substance claim
No
Drug product claim
No
Assignee
Alnylam Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.